Trending...
- City of Boston Issues Reminders Ahead of Election Day in One Week
- Attorney Eric Chun Joins Bisnar Chase Personal Injury Attorneys, LLP
- Alessia Moccia of E-uphoria: Bridging Fashion, Art, and Technology in NYC
BOSTON and MILAN, Nov. 30, 2023 ~ Allotex Inc. and SpA, a leading biologics and device company specializing in vision correction therapies, has announced that Junson Capital has joined its investor syndicate. This additional capital will help support the expansion of the Company's production facility in preparation for market introduction and US clinical trials.
Dr. David Muller, Founder and CEO of Allotex, commented on the company's progress, saying, "This financing will allow Allotex to introduce our groundbreaking technology in Europe and Japan in early 2024 while actively working with the FDA to initiate clinical trials in the United States as soon as possible. The additional capital will help support the necessary expansion of our production facilities to increase capacity and ensure a steady supply of products."
Allotex's innovative approach uses laser-shaped human corneal allografts to reshape the cornea for the treatment of presbyopia, restoring lost reading vision which is caused by the natural aging process. With hundreds of millions of individuals worldwide seeking a safe, effective, and long-lasting alternative to spectacles and contact lenses for reading, Allotex is poised to make a major impact in the vison care marketplace.
More on Boston Chron
John White, Allotex Board member representing KCK MedTech commented on their published safety and efficacy results along with their 4-year follow-up saying it would boost market acceptance for both patients and refractive surgeons. He added that surgeons have had confidence in using human corneal allografts for over 70 years and are excited about the potential for their technology to restore reading vision to millions of people who have age related presbyopia.
Junson Capital has joined existing investors including KCK MedTech, Panakes, Supernova Invest, and Exor Ventures to complete the Series B financing. Wei Shen from Junson Capital expressed enthusiasm for joining the investor syndicate stating they were excited to partner with Allotex and contribute to advancing their groundbreaking therapies with potential to make a significant impact on global vision-correction market. Junson Capital is a global investment manager with long dedication to disruptive technology and healthcare leaders across venture capital, private equity, public markets, real estate and alternatives. Allotex was advised by Cukierman & Co. Life Sciences for this transaction.
Dr. David Muller, Founder and CEO of Allotex, commented on the company's progress, saying, "This financing will allow Allotex to introduce our groundbreaking technology in Europe and Japan in early 2024 while actively working with the FDA to initiate clinical trials in the United States as soon as possible. The additional capital will help support the necessary expansion of our production facilities to increase capacity and ensure a steady supply of products."
Allotex's innovative approach uses laser-shaped human corneal allografts to reshape the cornea for the treatment of presbyopia, restoring lost reading vision which is caused by the natural aging process. With hundreds of millions of individuals worldwide seeking a safe, effective, and long-lasting alternative to spectacles and contact lenses for reading, Allotex is poised to make a major impact in the vison care marketplace.
More on Boston Chron
- TCB Capital Advisors Congratulates Altoida & Gregor Diagnostics on 2024 Merit Awards Recognition
- CCHR: Helsinki Medical Code Allows Coerced Research on Mental Health Patients
- Together Estranged announces event series as part of Family Estrangement Awareness Month
- Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
- Secrets of Esus Revealed at Jupiter Inlet
John White, Allotex Board member representing KCK MedTech commented on their published safety and efficacy results along with their 4-year follow-up saying it would boost market acceptance for both patients and refractive surgeons. He added that surgeons have had confidence in using human corneal allografts for over 70 years and are excited about the potential for their technology to restore reading vision to millions of people who have age related presbyopia.
Junson Capital has joined existing investors including KCK MedTech, Panakes, Supernova Invest, and Exor Ventures to complete the Series B financing. Wei Shen from Junson Capital expressed enthusiasm for joining the investor syndicate stating they were excited to partner with Allotex and contribute to advancing their groundbreaking therapies with potential to make a significant impact on global vision-correction market. Junson Capital is a global investment manager with long dedication to disruptive technology and healthcare leaders across venture capital, private equity, public markets, real estate and alternatives. Allotex was advised by Cukierman & Co. Life Sciences for this transaction.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Hoodgeek Merges Pov Commentary On Culture, Entertainment, Politics, Music, Sports, And Technology
- Boston Streets Cabinet Announces Installation of New Edgerly Plaza
- MountainOne Receives ABA "Brand Slam" Award for Video Campaign
- Boot Scootin' for Scholarships: A Night of Music, Dancing, and Giving Back!
- Boston: Mayor Wu Announces Open Newbury: Holiday Stroll
- Boston: Traffic Advisory for November 1, 2024
- Boston: November is National Family Caregivers Appreciation and Alzheimer's Awareness Month
- Boston: Supporting Our Veterans
- Celebrating Boston's Unsung Heros
- Alaskan Artist Builds Business to Fight Global Exploitation Through Fashion
- John Atencio Hosts Legacy Of Love Bridal & Diamond Event This November
- Dogma Systems lanza Security@Dogma: Solución Integral para la Seguridad de la Información
- Fight or Flight.... at least one other option.... Anatomy and Psychology of a Crisis
- Weymouth Food Pantry's "Weekend Back Packs" Reaches 450 Children Across 9 Public Schools
- Vantiva's Targets for Net-Zero Greenhouse Gas Emissions by 2050 Validated by the Science Based Targets initiative
- Qualis welcomes Steven C. Miley as Vice President of Contracts
- 61 Global Learning Charter Public School Students Participate in Dual Enrollment Program
- Jann Klose Signs with The Royalty Network, Releases New Single
- New England Law | Boston Alumna Amy L. Blake Confirmed as Chief Justice of the Massachusetts Appeals Court
- Coker Announces Acquisition of Healthcare Consulting Firm, TTG Healthcare Advisors